South Korea Medical Device Registration

Unlock the South Korean market with expert regulatory guidance, KGMP compliance support, and an independent local regulatory representative, with Cisema.

We help foreign manufacturers of medical devices, IVDs, and digital medical products navigate the full MFDS registration process, comply with Korean regulatory requirements, and maintain regulatory and quality compliance throughout the entire product lifecycle. As your experienced local regulatory partner, we support your market entry into Korea from initial strategy and device classification through approval and post-market surveillance.

With an experienced local team in South Korea and deep knowledge of the Korean “Medical Device Act,” “IVD Act,” and “Digital Medical Products Act,” Cisema acts as your independent Korean regulatory representative and compliance partner. We provide comprehensive support for MFDS approvals, KGMP conformity assessment, technical documentation, regulatory planning, Korean labeling, UDI compliance, and ongoing lifecycle management.

South Korea is widely recognized as one of the most advanced healthcare and technology markets in Asia, combining sophisticated healthcare infrastructure, strong purchasing power, rapid adoption of innovative technologies, and increasing demand for digital healthcare solutions. Korea has become an especially important market for AI-based medical devices, Software as a Medical Device (SaMD), Digital Therapeutics (DTx), wearable healthcare technologies, advanced IVD solutions, and aesthetic medical devices.

As Korean regulations continue to evolve rapidly, regulatory authorities are placing increasing emphasis on cybersecurity, software lifecycle management, AI governance, post-market surveillance, and quality system compliance. Having an effective MFDS regulatory strategy and strong local regulatory support has therefore become increasingly important for successful market entry and long-term commercial success.

From regulatory pathway assessment and dossier preparation to KGMP coordination, clinical and performance evaluation support, and post-market compliance, Cisema helps simplify your path to market entry in South Korea while giving you long-term flexibility, transparency, and control.

South Korea Medical Device Registration Services

We guide you through every step of medical device registration in Korea. We take care of compliance with MFDS requirements, advising you on the optimal market entry pathway, test methods and helping you through the whole process to achieving your medical device registration certificate. 

Regulatory Strategy & Classification

Determine the appropriate Korean medical device or IVD classification under the MFDS four-class risk-based system
Conduct product classification and risk-level assessment
Assess the most suitable Korean registration pathway, including notification, certification, approval, innovative device, and fast-track routes

Technical Documentation & Localization Support

Prepare and review Korean-style STED technical documentation in accordance with MFDS requirements
Draft and localize Korean labels, IFUs, and UDI information
Support software validation, cybersecurity documentation, and Korean regulatory compliance review

Testing, KGMP & Technical Support

Coordinate import and domestic transportation of test samples within South Korea
Supervise testing at MFDS-designated laboratories, including electrical safety, EMC, biocompatibility, and performance testing
Support KGMP conformity assessment activities and clinical/performance evaluation strategies

Registration Application & Submission

Create and manage MFDS online business accounts and application submissions
Prepare and submit Class I notifications, Class II certifications and approvals, and Class III & IV approval applications
Manage MFDS communications and supplementary responses

Post-Approval & Lifecycle Support

Ongoing regulatory compliance throughout the product lifecycle
Regulatory document management and maintenance
Strategic advice and support on license renewal, reclassification, post-approval deficiency letters, change applications and renewals

Local Authorized Representative Services for Korea

All foreign manufacturers of medical devices, IVDs, and digital medical products entering the South Korean market without a physical office in South Korea must appoint a local authorized representative, known as the Korean License Holder (KLH), as their in country representative. The KLH must be a legal entity residing in South Korea and acts as the legal license holder and regulatory liaison before the Ministry of Food and Drug Safety (MFDS) throughout the entire product lifecycle.

For overseas manufacturers, the KLH is not simply a filing agent. The KLH plays a central role in controlling and maintaining access to the Korean market and is responsible for managing submissions to the MFDS.

While appointing a distributor as KLH may initially appear commercially convenient, it can also create long-term limitations regarding distribution flexibility, certificate control, and intellectual property protection. Many manufacturers therefore prefer working with an independent regulatory partner to maintain greater commercial flexibility and long-term control of registrations.

The KLH compiles the STED and other application files in Korean and submits the completed dossier through the MFDS electronic submission portal.

At Cisema, we act as an independent Korean License Holder (KLH), providing manufacturers with transparent regulatory support while allowing full flexibility in selecting or changing distributors as business needs evolve.

Korea Legal Representation

Acting as local authorized representative and Korea License Holder (KLH)
MFDS communication and regulatory liaison
Regulatory representation before Korean authorities
Management of importer obligations

Regulatory Coordination

Ongoing regulatory updates
Inspection coordination
Customs and import support

Regulatory Compliance

Regulatory document management and maintenance
Korean labeling support, e-IFU and UDI support
KGMP coordination support

Post-Market Vigilance

Handle adverse event reporting and regulatory notifications
Coordinate Field Safety Corrective Actions (FSCAs), recalls, and corrective submissions
Support full conformity with South Korean market safety requirements

Conformity Assessment Bodies Collaboration

Provide documentation for audits by a registered CAB
Assist with conformity assessment requirements tied to device classification and risk

Regulatory Strategy

Guide your implementation of a Korea-compliant quality management system
Advise on rollout strategies and expansion across Asia Pacific

Global Communication

Provide multilingual support in English, Mandarin, German, and more
Align with your commercial, regulatory, and quality teams across time zones.

Why Work with Cisema?

One Partner, Full Lifecycle Support

From pre-market strategy to post-market compliance, we provide support to internal regulatory teams and ensure seamless lifecycle management.

Regional Reach, Global Presence

Based in Asia and Europe with a global team delivering global reach.

Cross-Industry Expertise

Pharma, biotech, medical devices, cosmetics, supplements, veterinary, industrial and consumer goods.

Proven Results

Over 20 years of regulatory submissions, regulatory expertise, and approvals to drive business success.

Role of a China Agent

Discover Our Other Medical Device Consulting Services in Southeast Asia

Malaysia

Singapore

Vietnam

Taiwan

Indonesia

The Philippines

Thailand

China

Hong Kong

Latest Insights

View More

Malaysia NPRA Updates Cosmetic Ingredient Requirements Under the ASEAN Cosmetic Directive

Circular No. 2/2026 revises prohibited, restricted, colorant, and preservative requirements for cosmetics marketed in Malaysia.

August 20, 2026
Malaysia NPRA Updates Cosmetic Ingredient Requirements Under the ASEAN Cosmetic Directive

China Overhauls Cosmetic Safety Rules with GB 7916-2026: Is Your Brand Ready?

Brands must audit ingredients, suppliers and packaging before January 2028 to ensure compliance with GB 7916-2026.

August 18, 2026
China Overhauls Cosmetic Safety Rules with GB 7916-2026: Is Your Brand Ready?
Scientist in clean modern room inspects cosmetics.

China Expands Animal Testing Data Exemptions in Major Cosmetics Registration and Filing Reform

Companies can benefit from expanded toxicology data exemptions, simplified cosmetics registration procedures, and more efficient compliance pathways

August 18, 2026
China Expands Animal Testing Data Exemptions in Major Cosmetics Registration and Filing Reform

Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites

As of July 1, 2026, Taiwan has completed its cosmetic GMP rollout, extending mandatory ISO 22716-based manufacturing standards to nearly all cosmetic factories

August 18, 2026
Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites

China Updates New Cosmetic Ingredient Registration Rules: Several Higher-Risk Ingredient Categories Removed

New NCI rules reduce administrative burden, streamline dossiers, and expand opportunities to reuse existing safety data.

August 18, 2026
China Updates New Cosmetic Ingredient Registration Rules: Several Higher-Risk Ingredient Categories Removed
This stock photo features a close-up, high-angle shot focusing on a skincare product arrangement set against a light-colored, wood-grain surface.

NMPA Opens Consultation on Two Draft Cosmetic Adverse Reaction Standards: Cosmetic Cheilitis & Cosmetic Contact Urticaria

Review China's new draft standards for cosmetic cheilitis and contact urticaria before the August 15, 2026, consultation deadline.

August 18, 2026
NMPA Opens Consultation on Two Draft Cosmetic Adverse Reaction Standards: Cosmetic Cheilitis & Cosmetic Contact Urticaria
Previous
Previous

Get in Touch with Our Medical Devices Team

And discover how we can support you in achieving approval for your medical device or IVD in South Korea.

Request Proposal